Acidic and basic fibroblast growth factors (aFGF and bFGF) are growth factors which may have a physiological role in the normal breast and in breast cancer. A study of the effects of aFGF and bFGF on a variety of breast cell lines and epithelial cells purified from normal breast organoids showed that whereas normal breast cells did not exhibit membrane ruffling in response to either of these growth factors, some breast cancer cell lines did. This difference was not due to lack of receptor since all the cell lines tested were mitogenically stimulated by bFGF. Dominant negative mutations of FGF receptor 3 (FGFR-3) and the
INTRODUCTION
The fibroblast growth factors (FGFs) belong to a family of growth regulatory proteins which induce the proliferation and differentiation of a wide range of cells of epithelial, mesodermal and neuroectodermal origin [1] [2] [3] [4] . Nine members of the FGF family have been identified, sharing 35-50% homology. Of these, int-2, hst/K-FGF, FGF-5, FGF-6 and KGF are synthesized with an N-terminal hydrophobic signal sequence leading to the normal secretory pathway, whereas acidic FGF (aFGF) and basic FGF (bFGF) have no such secretory signal [5, 6] . There is evidence for release of aFGF and bFGF possibly through leakage from damaged cells but perhaps from viable cells through a novel mechanism [7] [8] [9] .
The response of cells to FGF is mediated through formation of a ternary complex of growth factor, proteoglycan and highaffinity receptor [10] [11] [12] [13] [14] . A family of tyrosine kinase receptors which bind to FGFs including FGF receptor 1 (FGFR-1) [15, 16] , FGFR-2 [16] [17] [18] , FGFR-3 [19] and FGFR-4 [20] has emerged. There is extensive diversity within the high-affinity FGF receptors with splice variation producing alternative exon usage and truncated forms of receptor [21] [22] [23] [24] [25] .
bFGF and aFGF are both present in the breast. bFGF has been localized to the myoepithelial cells of normal breast by immunocytochemistry of paraffin sections [26] . bFGF has also been detected in breast cancer cell lines by Western blotting and immunocytochemistry (Bansal, G. S., Yiangou, C., Coope, R., Gomm, J. J., Johnston, C. L. and Coombes, R. C., unpublished work). aFGF is released from breast cancer biopsies and can be detected by Western blotting and a soft-agar bioassay [27] . Receptors for aFGF and bFGF are found in breast cancer cells. FGFR-1 and FGFR-2 were detected in normal epithelial and breast cancer cell lines by PCR of cDNA made from cellular mRNA [28] . However, Northern blotting revealed that is expressed at higher levels than FGFR-1 in breast cancer cell small GTP-binding protein p21rac inhibited membrane ruffling, showing that receptor dimerization and phosphorylation and p21rac activation are prerequisites for membrane ruffling in response to aFGF and bFGF. Transient transfection of individual FGFRs into cos-7 cells showed that FGFR-1, FGFR-2 and FGFR-3 could not mediate a membrane ruffling response whereas FGFR-4 could. These studies elucidate one signalling mechanism of FGF and point to differences in the response of normal and cancer breast epithelial cells which may be important in cell motility.
lines [29] . A study of 30 primary breast tumours showed 10 % of the samples having 2-4-fold amplification of FGFR-4 DNA by Southern blotting, indicating that FGFR-4 may have a role in breast tumourigenesis [30] . An analysis of FGF receptor mRNAs expressed in breast cancer cell lines revealed the presence of FGFR-1, FGFR-3 and FGFR-4 [31] . Since breast cancer cell lines contain receptors for aFGF and bFGF and will be exposed to both these growth factors in the breast, it is of interest to examine how these growth factors will effect the breast cancer cells. bFGF has been shown to be mitogenic to human breast cancer cell lines and cultured epithelial cells derived from normal and malignant breast biopsies [32, 33] . bFGF also stimulates plasminogen activator in breast tumour cell lines [34] . This enzyme is thought to be important in angiogenesis and may also be involved in the degradation of the basement membrane and subsequent tumour invasion into the surrounding stromal tissue [35] . We wished to investigate whether bFGF and aFGF could affect motility of breast cells and we used the phenomenon of membrane ruffling to assess this.
Membrane ruffles are specialized plasma membrane ultrastructures of mammalian cells which are thought to have roles in growth, development and locomotion [36, 37] . Migrating fibroblasts form membrane ruffles at their leading edges and this is believed to play a fundamental role in directional migration.
Membrane ruffles contain fine actin filaments and may be visualized using a fluorescently labelled phalloidin. A variety of growth factors and the oncogene p21ras are able to transiently induce circular membrane ruffling in serum-starved cells [38] [39] [40] . In addition, microinjection of the small GTP binding protein p21rac into fibroblasts was found to induce membrane ruffling [41] . We Figure 1 and 157, SKBR3 and MCF7 exhibited membrane ruffling in response to both FGFs. These cells gave some response after treatment with 3 ng/ml of aFGF but maximal stimulation required 30 ng/ml of aFGF and aFGF elicited a more pronounced response than bFGF. However, the converse situation was true for Swiss3T3 cells where bFGF promoted the greater response.
Normal epithelial cells were purified from an organoid preparation from a normal breast by immunomagnetic separation.
The purified epithelial cells were tested for membrane ruffling in response to aFGF and bFGF and, similarly to all the normal breast cell lines tested, did not respond at concentrations of growth factor up to 50 ng/ml (Figure 1, E and F) . In summary, no normal breast cells exhibited membrane ruffling in response to growth factor, however some cancer cell lines did respond in this way.
In order to investigate whether the lack of membrane ruffling in HBR-SVI61, HBL-100, MCF1OA, ZR-75 and MDA-MB-231 cell lines is due to the absence of FGFRs in these cell lines, the cells were stimulated with bFGF and their mitogenic response assessed using a [3H]thymidine incorporation assay. As shown in 
FGF-induced membrane ruffling is inhibited by a dominant negative FGFR-3
In order to show that high-affinity FGFRs are involved in transducing membrane ruffling, a dominant negative FGFR-3 construct was made. A stop codon was introduced eight amino acids after the transmembrane domain of FGFR-3 so that a truncated receptor would be translated (Table 3 ). FGFR-3 was chosen as the receptor to be mutated in preference to FGFR-1 since FGFR-1 has been reported not to mediate membrane ruffling [44] . No information was available as to which of the remaining FGFRs might mediate membrane ruffling so FGFR-3 was chosen at random from this group. Since heterodimerization between different classes of FGFR has been observed, it was hoped that a truncated FGFR-3 might inhibit signalling through more than one class of receptor [45, 46] . The truncated FGFR-3 was subcloned into a pSG5 eukaryotic expression vector and was introduced together with pUC-puro into Swiss3T3 and T47D cells by electroporation. The number of puromycin-resistant colonies achieved was similar to that produced by the puromycin resistance plasmid alone, showing that the truncated FGFR-3 was not toxic to either cell line (Table  3) . Puromycin-resistant colonies were tested for overexpression of FGFR-3 by immunoflorescence (results not shown) and two positive cell lines were selected. The ability of the truncated FGFR-3 to inhibit the action of aFGF and bFGF in the transfected cell lines was assessed by using a [3H]thymidine incorporation assay. As shown in Figure  2 We tested whether the dominant negative FGFR-3 was able to inhibit membrane ruffling. As shown in Figure 3 Table 4 ). Therefore it would be predicted that FGFR phosphorylation is required for membrane ruffling to occur. The actual member(s) of the FGFR family mediating this effect cannot be predicted, however either FGFR-3 or a receptor able to dimerize with it must be involved.
A dominant negative mutant of p2lrac inhibits membrane ruffling in Swiss3T3 and T470 cells An N 17 mutation of p21rac has previously been shown to act as a dominant negative [41] . N17 rac cDNA, obtained from Dr. A. Hall's laboratory (MRC Laboratory for Molecular Cell Biology, University College London), was subcloned into a eukaryotic expression vector (pSG5) and was introduced together with a puromycin resistance vector into Swiss3T3 and T47D cells by electroporation. As shown in Table 3 , co-expression of N17p2lrac with a puromycin resistance plasmid substantially reduced the number of puromycin resistant colonies. This indicates that N17p2lrac may be toxic to cells. Owing to the difficulty in achieving N17p2lrac-expressing cells, a transient expression system was used to study the effect of N17p2lrac.
As shown in Table 4 , Swiss3T3 cells electroporated in the presence of pSG5 vector exhibited membrane ruffling when stimulated with 10 ng/ml of aFGF or bFGF. However, transient expression of N17p21rac was able to inhibit membrane ruffling in response to aFGF and bFGF ( Figure 3, E and F) . Similarly for T47D cells, electroporation in the presence of pSG5 vector allowed cells to exhibit membrane ruffling in response to aFGF and bFGF but expression of N17p21rac was able to inhibit this effect ( Figure 4, E and F) . This indicates that, similarly to platelet-derived growth factor (PDGF) signalling, activation of p21rac is required for membrane ruffling in response to FGFs. FGFR-4 is the receptor involved in the membrane ruffling response In order to investigate which of the FGFRs is involved in the membrane ruffling response, cos-7 cells were transiently transfected with individual receptors and tested for their ability to give a membrane ruffling response after treatment with heparin and a mixture of aFGF and bFGF. Cos-7 cells were selected for this experiment since they are able to give a membrane ruffling response to EGF but not to aFGF or bFGF even in the presence of heparin ( Figure 5, A and B) . This suggests that their failure to give this response is due to lack of receptors that recognise human aFGF or bFGF. Cells shown to be expressing FGFR-1, FGFR-2 or FGFR-3 by immunofluorescence, failed to show membrane ruffling after treatment with 1 ug/ml of heparin, 20 ng/ml of aFGF and 20 ng/ml bFGF ( Figure 5, C, D 
DISCUSSION
A number of growth factors cause changes in the state of actin polymerization in cells. One consequence of this is the phenomenon of membrane ruffling in which actin polymerizes in fine filaments at the plasma membrane. Membrane ruffling is associated with cell motility and therefore could be important in determining the metastatic potential of cells. Both bFGF and aFGF are present in the breast with bFGF being produced in myoepithelial cells [26] and aFGF being associated with endothelial cells present especially in vascularized tumours [27, 47] . We were interested to see whether aFGF and bFGF could affect cells by causing membrane ruffling. Using Swiss3T3 cells both these growth factors were able to do so.
A range of breast cell lines were tested for membrane ruffling and although none Whichever mechanism is involved, the ability of breast cancer cells to ruffle in response to growth factors which they will be exposed to within the breast may indicate a greater motility and a greater ability to metastisize. It will be of interest to find the basis of this difference. We wished to investigate the pathway by which aFGF and bFGF produce membrane ruffling. Most of the cells' responses to FGFs are mediated through the family of high-affinity receptors, however some proteoglycans like syndecan have some biological activity after binding of growth factor [48] . The cytoplasmic domain of syndecan associates with the actin cytoskeleton and it could be envisioned that membrane ruffling could be mediated through this interaction, without the involvement of high-affinity receptors. A dominant negative mutation of FGFR-3 was used to address this question. A truncated FGFR-1 containing the extracellular and transmembrane domains only, has previously been shown to act as a dominant negative inhibitor of FGF action [46] . It presumably works by dimerizing with full length receptor and preventing tyrosine phosphorylation from occurring. There is some evidence indicating that different classes of FGFR can dimerize with each other, allowing the possibility that one class of truncated receptor can inhibit signalling through different FGFRs [45, 46] . The ability of FGFR-3 to completely inhibit growth in response to aFGF and bFGF suggests that this is indeed the case, so that truncated FGFR-3 would inhibit a signal mediated through FGFR-1, 2 and 4 as well as FGFR-3. Our results indicate that membrane ruffling is mediated through high-affinity receptors since a truncated FGFR-3 is able to inhibit this effect.
We have used transiently transfected cos-7 cells to address the question of which FGFR is responsible for the membrane ruffling response and we find that FGFR-4 is the only receptor class tested that can produce this response. A previous report showed that FGFR-1 does not mediate membrane ruffling and our results are in agreement with this [44] . Various studies have indicated that P13 kinase activation may be required for membrane ruffling since mutation of receptor tyrosines to which p85 binds leads to loss of membrane ruffling [49] , and wortmannin, an inhibitor of P13 kinase, inhibits membrane ruffling [50] . The SH2 domain ofp85 recognises the phosphotyrosine motif YXXM [51] . Such a motif is present near the C-terminus of all four classes of FGFR, however in the case of FGFR-1 it has not been reported as one of the tyrosine phosphorylation sites [52] . It is possible that the ability of FGFRs to elicit a membrane ruffling response will be dependent on the ability of the YXXM motif to be phosphorylated efficiently. Gene amplification and relatively high expression levels for FGFR-4 have been found in breast cancer cells [29, 30] It is possible that increased levels of FGFR-4 account for the membrane ruffling ability of breast cancer cell lines. The involvement of FGFR-4 would also explain the greater ruffling response to aFGF since FGFR-4 has a higher affinity for aFGF than bFGF [29] . However, in the case of Swiss3T3 cells, bFGF gave a greater ruffling response indicating that in these cells an additional receptor may be important. p21rac has previously been shown to be involved in the signal transduction pathway leading to membrane ruffling [41] . We wanted to know whether FGF stimulation uses a similar pathway to that already demonstrated for PDGF. To ascertain this, we used a dominant negative mutant of p21rac. Overexpression of N1 7p21rac in both Swiss3T3 and T47D cells led to cell death, showing that this protein is toxic to cells when present in high amounts. It is unlikely that inhibition of membrane ruffling alone is responsible for the observed toxicity, however p21 rac may control a number of different activities and one of these may be responsible for the toxic effect. p21rac has a second function in neutrophils where it controls the production of superoxide [53] . It is of interest to note that the Saccharomyces cerevisiae CDC42, similar to p21rac, has a role in positioning bud formation before cell division in budding yeast [54, 55] . It is possible that p2lrac has some similar role in cell division which may account for a dominant negative inhibitor preventing cells from growing. Alternatively, the toxicity of p2lrac could result from inhibition of ras activation by sequestering an important exchange factor. One exchange factor for ras has two separate exchange factor domains, one which activates p2lras and a second having homology with exchange factors which activate proteins in the rho-like family of small GTPases which includes p2lrac [56] . Sequestering 
